Skip to content

Warm Homes for Elder New Zealanders

Warm Homes for Elder New Zealanders: a Community Trial of People With COPD

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01627418
Acronym
WHEZ
Enrollment
522
Registered
2012-06-25
Start date
2009-04-30
Completion date
2013-02-28
Last updated
2015-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease

Keywords

COPD, CORD, COAD

Brief summary

Aim The purpose of this study is to evaluate whether fuel subsidies reduce exacerbations of COPD among people aged over 55, and therefore whether providing such subsidies is a cost-beneficial policy initiative. The Warm Homes for Elder New Zealanders Study enrolled community-dwelling people aged over 55 with moderate or worse COPD. Prior to the study commencing the houses were insulated (if feasible, & the house-owner agreed). Data were collected on the health and energy use of the participants. The households randomly assigned to the early intervention group had a subsidy to their power account their first winter in the study. The subsidy was the intervention and was designed to enable the participants, if they chose to do so, to keep their house warmer during the winter.

Detailed description

Warm Homes for Elder New Zealanders (WHEZ) Background Although there has been considerable recent work on the prevention, management and causes of Chronic Obstructive Pulmonary Disease (COPD), the contribution of housing has not been well researched. This is despite the socio-economic patterning of COPD (Maori women have the highest rate of COPD that has been recorded for any group of women), and the relationship between socio-economic deprivation and housing conditions. It is likely that improved heating would reduce exacerbations of COPD as: * COPD patients with the most advanced disease tend to be older people who often live on a fixed income and may be unable to afford adequate heating * There is a high excess of winter hospitalisations in COPD patients indicating COPD exacerbations may be triggered by cold conditions. * About one third of exacerbations of COPD are triggered by respiratory infections. * The Housing, Insulation and Health Study demonstrated a reduction in self-reported respiratory disease after houses were insulated. Therefore improving the heating in households with a COPD patient may reduce respiratory infections and this in turn would reduce the number and severity of exacerbations. The percentage of people over 65 in New Zealand will increase from 12% to 22% over the next 25 years. Therefore it will become increasingly important to find cost-effective ways of reducing the morbidity of the older age group. As COPD is a significant cause of morbidity amongst older people, this study investigates a potentially cost effective intervention to reduce both the likelihood of expensive hospital stays and improve the quality of life for older people. Aim To evaluate whether fuel subsidies reduce exacerbations of COPD among people aged over 55, and therefore whether providing such subsidies is a cost-beneficial policy initiative. Potential Benefits The potential benefits of the study include reducing the burden of disease. The patients and their caregivers may experience improved quality of life. Hospitals may experience fewer patients requiring treatment during the winter. A cost-benefit analysis will quantify the benefits.

Interventions

BEHAVIORALEnergy Voucher

Receive the intervention the first winter enrolled in the study. The intervention is a electricity voucher and a short pamphlet describing how to work out how much heat the voucher can buy.

BEHAVIORALNo intervention : control arm

Do not receive the money or pamphlet in the initial study year

Sponsors

Health Research Council, New Zealand
CollaboratorOTHER
University of Otago
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
55 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Post Bronchodilator FEV1/FVC ratio \< Lower Limit of Normal (NHanesIII) * Post Bronchodilator FEV1 \< 80% of the predicted FEV1 (NHanesIII) OR - In the last three years either went to hospital for their COPD or took antibiotics/steriods for their COPD

Exclusion criteria

* Not planning to stay in the same dwelling until the end of the study * Does not want to take part in research * Unwilling to answer inclusion questionnaire * Unable to communicate effectively

Design outcomes

Primary

MeasureTime frame
Moderate or severe exacerbations of COPD during winter for which hospitalisation, systemic corticosteroids and/or antibiotics are required to treat the exacerbationFour months

Secondary

MeasureTime frame
Moderate exacerbations of COPD during winter; which will be defined as requiring treatment with systemic corticosteroids and/or antibioticsFour months
All-cause hospitalisation during winterFour months
Temperature in the living and bedrooms during winterFour months
Electricity usage during winterFour months
Costs to health care system of index participant during winterFour months
Severe exacerbations of COPD during winter for which hospitalisation is required to treat the exacerbationFour months
Respiratory health of other people living in household during winterFour months
Any changes in index participant baseline lung functioncourse of study ( up to 18 months)
Study withdrawals due to death or greater dependencycourse of study (up to 18 months)
Support person burdencourse of study (up to 18 months)
Self-reported quality of life for index participant during winterFour months

Countries

New Zealand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 24, 2026